- Aminoven 8 and 16 is licensed for administration to adults, children and adolescents (2-18 years). For children under 2 years, paediatric amino acid preparations which are formulated to meet their different metabolic needs should be used
- Aminoven 25 is for use in adults only and is mainly indicated where the parenteral nutrition therapy needs the fluid volume to be restricted
Aminoven® 8,16,25
(amino acids 5%, 10%, 15%)
- Filename
- Macronutrient Prescribing Information.pdf
- Size
- 209 KB
- Format
Details
- Benefits
- Composition
- Features
- Indication
- Presentation and order codes
g/l = grams per litre
| Product | Amino acids g/l | Nitrogen g/l |
|---|---|---|
| Aminoven 8 | 50 | 8.1 |
| Aminoven 16 | 100 | 16.2 |
| Aminoven 25 | 150 | 25.7 |
- Amino acid solutions containing taurine
- Provides essential and non-essential amino acids
- Provides a source of branched-chain amino acids
- Comes in 3 concentrations to suit a variety of patient needs
Aminoven 8 and 16: For supply of amino acids as part of a parenteral nutrition regimen. Amino acid solutions should be administered generally in combination with adequate amounts of energy supplements
Aminoven 25: For supply of amino acids as part of a parenteral nutrition regimen. Aminoven 25 is mainly indicated if during parenteral nutrition therapy the fluid volume has to be restricted. Amino acid solutions should be administered generally in combination with adequate amounts of energy supplements
Please refer to the summary of product characteristics for further information and before prescribing.
Aminoven 25: For supply of amino acids as part of a parenteral nutrition regimen. Aminoven 25 is mainly indicated if during parenteral nutrition therapy the fluid volume has to be restricted. Amino acid solutions should be administered generally in combination with adequate amounts of energy supplements
Please refer to the summary of product characteristics for further information and before prescribing.
| Aminoven® | |||
|---|---|---|---|
| Item description | Unit Size | Case Qty | Item Code |
| Aminoven® 8 | 500ml | 10 | 3874091 |
| Aminoven® 16 | 500ml | 10 | 3871091 |
| Aminoven® 25 | 250ml | 10 | 3877061 |
| 500ml | 10 | 3877091 | |
| 1000ml | 6 | 3877141 | |
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk Adverse events should also be reported to Fresenius Kabi Limited. Email: Pharmacovigilance.GB@fresenius-kabi.com
GB-Amvn-2400009 January 2025